| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soft Tissue Neoplasms | 213 | 2023 | 1361 | 22.440 |
Why?
|
| Sarcoma | 109 | 2023 | 1895 | 9.380 |
Why?
|
| Histiocytoma, Benign Fibrous | 44 | 2018 | 109 | 5.110 |
Why?
|
| Lipoma | 34 | 2023 | 334 | 5.080 |
Why?
|
| Liposarcoma | 45 | 2023 | 333 | 4.880 |
Why?
|
| Myoepithelioma | 18 | 2020 | 43 | 4.260 |
Why?
|
| Immunohistochemistry | 207 | 2023 | 11363 | 4.230 |
Why?
|
| Gene Fusion | 21 | 2022 | 371 | 4.060 |
Why?
|
| Skin Neoplasms | 96 | 2023 | 5662 | 3.970 |
Why?
|
| Neurilemmoma | 27 | 2021 | 547 | 3.290 |
Why?
|
| Fibroma | 25 | 2020 | 212 | 3.270 |
Why?
|
| In Situ Hybridization, Fluorescence | 77 | 2023 | 2638 | 3.220 |
Why?
|
| Leiomyosarcoma | 39 | 2022 | 477 | 2.950 |
Why?
|
| Oncogene Proteins, Fusion | 32 | 2023 | 1581 | 2.940 |
Why?
|
| Gastrointestinal Neoplasms | 31 | 2023 | 987 | 2.780 |
Why?
|
| Neoplasms, Muscle Tissue | 16 | 2020 | 83 | 2.730 |
Why?
|
| Gene Rearrangement | 29 | 2021 | 1179 | 2.710 |
Why?
|
| Fibrosarcoma | 30 | 2023 | 348 | 2.660 |
Why?
|
| Nerve Sheath Neoplasms | 19 | 2021 | 190 | 2.620 |
Why?
|
| Epithelioid Cells | 16 | 2021 | 71 | 2.620 |
Why?
|
| Proto-Oncogene Proteins c-kit | 39 | 2013 | 774 | 2.610 |
Why?
|
| Gastrointestinal Stromal Tumors | 26 | 2020 | 642 | 2.440 |
Why?
|
| Solitary Fibrous Tumors | 10 | 2021 | 72 | 2.380 |
Why?
|
| Hemangioendothelioma, Epithelioid | 10 | 2021 | 54 | 2.200 |
Why?
|
| Hemangiosarcoma | 23 | 2019 | 236 | 2.150 |
Why?
|
| Translocation, Genetic | 32 | 2022 | 1417 | 2.070 |
Why?
|
| Hemangioendothelioma | 12 | 2020 | 121 | 1.970 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 9 | 2023 | 75 | 1.930 |
Why?
|
| Calmodulin-Binding Proteins | 13 | 2022 | 249 | 1.910 |
Why?
|
| Oncogene Fusion | 13 | 2021 | 99 | 1.860 |
Why?
|
| Fasciitis | 5 | 2021 | 65 | 1.770 |
Why?
|
| Hemangioma | 18 | 2023 | 737 | 1.760 |
Why?
|
| Myofibroma | 4 | 2017 | 50 | 1.730 |
Why?
|
| Testicular Neoplasms | 12 | 2023 | 761 | 1.710 |
Why?
|
| Angiofibroma | 11 | 2023 | 68 | 1.710 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 5 | 2023 | 37 | 1.700 |
Why?
|
| Bone Neoplasms | 28 | 2023 | 2522 | 1.690 |
Why?
|
| Adult | 396 | 2023 | 213712 | 1.680 |
Why?
|
| Vascular Neoplasms | 7 | 2021 | 175 | 1.660 |
Why?
|
| Middle Aged | 377 | 2023 | 213127 | 1.610 |
Why?
|
| RNA-Binding Protein EWS | 15 | 2023 | 216 | 1.610 |
Why?
|
| S100 Proteins | 38 | 2022 | 259 | 1.600 |
Why?
|
| Diagnosis, Differential | 115 | 2021 | 12958 | 1.590 |
Why?
|
| RNA-Binding Protein FUS | 9 | 2021 | 72 | 1.550 |
Why?
|
| Pathology, Clinical | 4 | 2023 | 368 | 1.520 |
Why?
|
| Retroperitoneal Neoplasms | 12 | 2015 | 334 | 1.520 |
Why?
|
| Hemangiopericytoma | 8 | 2016 | 77 | 1.510 |
Why?
|
| Desmin | 24 | 2019 | 130 | 1.500 |
Why?
|
| Aged | 289 | 2023 | 162944 | 1.470 |
Why?
|
| Rhabdomyosarcoma | 22 | 2018 | 382 | 1.450 |
Why?
|
| Male | 437 | 2023 | 349538 | 1.440 |
Why?
|
| Adolescent | 194 | 2023 | 85649 | 1.420 |
Why?
|
| Rhabdomyoma | 3 | 2022 | 57 | 1.410 |
Why?
|
| Glomus Tumor | 5 | 2022 | 66 | 1.410 |
Why?
|
| Myofibroblasts | 4 | 2021 | 221 | 1.380 |
Why?
|
| beta Catenin | 6 | 2023 | 1058 | 1.380 |
Why?
|
| Dermatofibrosarcoma | 11 | 2018 | 62 | 1.370 |
Why?
|
| Female | 450 | 2023 | 379592 | 1.370 |
Why?
|
| Immunoenzyme Techniques | 55 | 2012 | 1799 | 1.360 |
Why?
|
| Myxoma | 11 | 2022 | 130 | 1.360 |
Why?
|
| Transcription Factors | 39 | 2022 | 12164 | 1.340 |
Why?
|
| Abdominal Neoplasms | 8 | 2012 | 290 | 1.330 |
Why?
|
| Humans | 658 | 2023 | 742088 | 1.320 |
Why?
|
| Vulvar Neoplasms | 9 | 2015 | 272 | 1.320 |
Why?
|
| Antigens, CD34 | 22 | 2012 | 657 | 1.300 |
Why?
|
| Sarcoma, Synovial | 15 | 2020 | 164 | 1.300 |
Why?
|
| Neoplasm Recurrence, Local | 64 | 2022 | 9185 | 1.230 |
Why?
|
| Histiocytoma, Malignant Fibrous | 6 | 2014 | 63 | 1.210 |
Why?
|
| Genital Neoplasms, Male | 5 | 2022 | 74 | 1.200 |
Why?
|
| Receptor, trkA | 8 | 2022 | 164 | 1.180 |
Why?
|
| Neoplasm Proteins | 32 | 2021 | 3691 | 1.170 |
Why?
|
| Piperazines | 29 | 2013 | 2488 | 1.160 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 6 | 2023 | 105 | 1.160 |
Why?
|
| Child | 155 | 2023 | 77478 | 1.150 |
Why?
|
| Neoplasms, Fibrous Tissue | 4 | 2022 | 25 | 1.140 |
Why?
|
| Stromal Cells | 23 | 2021 | 1353 | 1.130 |
Why?
|
| Neoplasms, Vascular Tissue | 10 | 2003 | 35 | 1.120 |
Why?
|
| International Normalized Ratio | 2 | 2019 | 365 | 1.110 |
Why?
|
| Young Adult | 90 | 2023 | 56350 | 1.090 |
Why?
|
| Pyrimidines | 30 | 2013 | 2933 | 1.090 |
Why?
|
| Liposarcoma, Myxoid | 11 | 2021 | 64 | 1.090 |
Why?
|
| Aged, 80 and over | 124 | 2023 | 57683 | 1.070 |
Why?
|
| Leiomyoma | 16 | 2015 | 728 | 1.040 |
Why?
|
| Giant Cell Tumors | 6 | 2017 | 99 | 1.030 |
Why?
|
| Repressor Proteins | 13 | 2022 | 3020 | 1.020 |
Why?
|
| Myoma | 3 | 2017 | 10 | 0.980 |
Why?
|
| Dermis | 4 | 2011 | 207 | 0.970 |
Why?
|
| Chromosome Aberrations | 29 | 2023 | 1811 | 0.950 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2022 | 484 | 0.930 |
Why?
|
| Sarcoma, Small Cell | 4 | 2017 | 22 | 0.910 |
Why?
|
| Cell Dedifferentiation | 5 | 2019 | 135 | 0.900 |
Why?
|
| Genital Neoplasms, Female | 5 | 2022 | 516 | 0.880 |
Why?
|
| Sertoli Cell Tumor | 4 | 2023 | 40 | 0.870 |
Why?
|
| Extremities | 12 | 2012 | 865 | 0.860 |
Why?
|
| Child, Preschool | 84 | 2023 | 40955 | 0.860 |
Why?
|
| HMGA2 Protein | 7 | 2017 | 123 | 0.840 |
Why?
|
| DNA-Binding Proteins | 24 | 2020 | 9639 | 0.840 |
Why?
|
| Mucin-1 | 14 | 2014 | 543 | 0.830 |
Why?
|
| Granuloma, Plasma Cell | 8 | 2015 | 83 | 0.820 |
Why?
|
| Proto-Oncogene Proteins | 21 | 2020 | 4553 | 0.810 |
Why?
|
| Chondrosarcoma, Mesenchymal | 2 | 2020 | 15 | 0.810 |
Why?
|
| Drug Monitoring | 2 | 2019 | 956 | 0.810 |
Why?
|
| Carcinoma | 13 | 2023 | 2374 | 0.810 |
Why?
|
| Biopsy | 23 | 2023 | 6756 | 0.810 |
Why?
|
| Mitotic Index | 13 | 2018 | 172 | 0.800 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 932 | 0.800 |
Why?
|
| Sarcoma, Clear Cell | 5 | 2023 | 76 | 0.800 |
Why?
|
| Karyotyping | 40 | 2011 | 1243 | 0.790 |
Why?
|
| Neurofibroma | 10 | 2010 | 106 | 0.790 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 5 | 2023 | 314 | 0.790 |
Why?
|
| Oncogene Proteins | 11 | 2018 | 749 | 0.780 |
Why?
|
| Pelvic Neoplasms | 6 | 2023 | 254 | 0.760 |
Why?
|
| Actins | 30 | 2022 | 2120 | 0.750 |
Why?
|
| RNA-Binding Proteins | 12 | 2016 | 1899 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2019 | 220 | 0.740 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2019 | 546 | 0.720 |
Why?
|
| Tumor Burden | 12 | 2022 | 1905 | 0.710 |
Why?
|
| Homeodomain Proteins | 5 | 2021 | 2417 | 0.710 |
Why?
|
| Cell Differentiation | 31 | 2022 | 11470 | 0.710 |
Why?
|
| Mitosis | 16 | 2023 | 1208 | 0.700 |
Why?
|
| Antigens, Neoplasm | 14 | 2017 | 1983 | 0.690 |
Why?
|
| Muscle Neoplasms | 3 | 2017 | 139 | 0.690 |
Why?
|
| Trans-Activators | 10 | 2021 | 2924 | 0.690 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 13 | 2010 | 379 | 0.690 |
Why?
|
| Muscle, Smooth | 10 | 2006 | 933 | 0.680 |
Why?
|
| Cell Transformation, Neoplastic | 13 | 2014 | 2940 | 0.680 |
Why?
|
| Mesenchymoma | 7 | 2004 | 47 | 0.680 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2022 | 449 | 0.680 |
Why?
|
| Prognosis | 52 | 2021 | 29010 | 0.670 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 971 | 0.670 |
Why?
|
| Uterine Neoplasms | 9 | 2023 | 1513 | 0.660 |
Why?
|
| Fibroblasts | 12 | 2020 | 4143 | 0.660 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2020 | 2455 | 0.660 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2019 | 200 | 0.650 |
Why?
|
| Infant | 61 | 2023 | 35070 | 0.640 |
Why?
|
| Angiomyolipoma | 4 | 2017 | 186 | 0.640 |
Why?
|
| Chromosomal Proteins, Non-Histone | 8 | 2017 | 730 | 0.640 |
Why?
|
| Point Mutation | 4 | 2022 | 1624 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2017 | 575 | 0.620 |
Why?
|
| Calcinosis | 7 | 2022 | 1497 | 0.620 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2018 | 234 | 0.620 |
Why?
|
| Benzamides | 29 | 2013 | 1378 | 0.610 |
Why?
|
| Neoplasms, Connective Tissue | 5 | 2023 | 40 | 0.600 |
Why?
|
| Peripheral Nervous System Neoplasms | 8 | 2001 | 123 | 0.600 |
Why?
|
| Prostatic Hyperplasia | 1 | 2021 | 522 | 0.600 |
Why?
|
| Thoracic Neoplasms | 3 | 2013 | 268 | 0.600 |
Why?
|
| Chondrosarcoma | 15 | 2016 | 309 | 0.590 |
Why?
|
| Serum Response Factor | 1 | 2017 | 81 | 0.590 |
Why?
|
| Mutation | 48 | 2023 | 29717 | 0.580 |
Why?
|
| Head and Neck Neoplasms | 10 | 2018 | 2712 | 0.580 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2017 | 188 | 0.580 |
Why?
|
| World Health Organization | 4 | 2014 | 1317 | 0.580 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2020 | 2915 | 0.570 |
Why?
|
| Keratins | 12 | 2008 | 515 | 0.560 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2016 | 31 | 0.560 |
Why?
|
| Nose Neoplasms | 3 | 2016 | 245 | 0.550 |
Why?
|
| Rhabdoid Tumor | 7 | 2016 | 212 | 0.550 |
Why?
|
| Myxosarcoma | 4 | 2022 | 15 | 0.540 |
Why?
|
| Mediastinal Neoplasms | 6 | 2012 | 421 | 0.540 |
Why?
|
| Muscle Development | 2 | 2017 | 271 | 0.540 |
Why?
|
| Transcription Factor RelA | 1 | 2017 | 275 | 0.540 |
Why?
|
| Connective Tissue | 6 | 2022 | 420 | 0.540 |
Why?
|
| Genes, p53 | 9 | 2013 | 755 | 0.540 |
Why?
|
| Neoplasm Invasiveness | 18 | 2014 | 3612 | 0.530 |
Why?
|
| Telomerase | 2 | 2021 | 729 | 0.530 |
Why?
|
| Hemosiderosis | 3 | 2011 | 71 | 0.520 |
Why?
|
| Neurothekeoma | 3 | 2007 | 7 | 0.510 |
Why?
|
| Neoplasms, Multiple Primary | 8 | 2012 | 600 | 0.500 |
Why?
|
| Tristetraprolin | 1 | 2014 | 42 | 0.490 |
Why?
|
| Treatment Outcome | 50 | 2022 | 62966 | 0.490 |
Why?
|
| Intestinal Neoplasms | 4 | 2019 | 319 | 0.490 |
Why?
|
| Nuclear Proteins | 19 | 2020 | 5851 | 0.490 |
Why?
|
| Neurofibromatosis 1 | 3 | 2017 | 562 | 0.480 |
Why?
|
| Melanoma | 14 | 2022 | 5462 | 0.460 |
Why?
|
| Fibroma, Ossifying | 4 | 2020 | 19 | 0.460 |
Why?
|
| Sarcoma, Endometrial Stromal | 2 | 2013 | 91 | 0.460 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 12 | 2023 | 1659 | 0.460 |
Why?
|
| Hemangioblastoma | 1 | 2014 | 70 | 0.450 |
Why?
|
| Microscopy, Electron | 22 | 2005 | 2645 | 0.450 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2011 | 297 | 0.450 |
Why?
|
| Appointments and Schedules | 1 | 2017 | 414 | 0.450 |
Why?
|
| Carney Complex | 2 | 2023 | 17 | 0.450 |
Why?
|
| Hamartoma | 7 | 2010 | 234 | 0.440 |
Why?
|
| DNA, Neoplasm | 16 | 2013 | 1758 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2014 | 286 | 0.440 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1126 | 0.440 |
Why?
|
| Anticoagulants | 2 | 2019 | 4595 | 0.430 |
Why?
|
| Disease-Free Survival | 21 | 2020 | 6891 | 0.430 |
Why?
|
| Nevus | 2 | 2012 | 204 | 0.430 |
Why?
|
| Kidney Neoplasms | 8 | 2022 | 4229 | 0.430 |
Why?
|
| Lymphangioma | 6 | 2003 | 65 | 0.430 |
Why?
|
| Indoles | 10 | 2014 | 1834 | 0.420 |
Why?
|
| Neoplasm Metastasis | 18 | 2019 | 4839 | 0.410 |
Why?
|
| Nail Diseases | 1 | 2012 | 51 | 0.410 |
Why?
|
| Predictive Value of Tests | 22 | 2022 | 15056 | 0.410 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2011 | 75 | 0.400 |
Why?
|
| Stomach Neoplasms | 5 | 2019 | 1327 | 0.400 |
Why?
|
| Granular Cell Tumor | 3 | 2005 | 51 | 0.400 |
Why?
|
| Pyrroles | 9 | 2009 | 1143 | 0.400 |
Why?
|
| Terminology as Topic | 8 | 2022 | 1548 | 0.400 |
Why?
|
| Skin | 11 | 2006 | 4353 | 0.400 |
Why?
|
| Neurofilament Proteins | 4 | 2008 | 318 | 0.400 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2020 | 223 | 0.390 |
Why?
|
| Hyalin | 2 | 2008 | 37 | 0.390 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2005 | 102 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 22 | 10 | 2014 | 351 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 23 | 2016 | 8425 | 0.390 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2011 | 133 | 0.390 |
Why?
|
| Sarcoma, Alveolar Soft Part | 2 | 2022 | 41 | 0.390 |
Why?
|
| Breast Neoplasms | 16 | 2022 | 20774 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1377 | 0.380 |
Why?
|
| Lung Neoplasms | 20 | 2022 | 13019 | 0.370 |
Why?
|
| Smooth Muscle Tumor | 1 | 2011 | 67 | 0.370 |
Why?
|
| Mouth Neoplasms | 4 | 2002 | 601 | 0.370 |
Why?
|
| Orbital Neoplasms | 3 | 2001 | 225 | 0.370 |
Why?
|
| Cell Nucleus | 14 | 2021 | 2968 | 0.370 |
Why?
|
| Histones | 4 | 2020 | 2597 | 0.370 |
Why?
|
| Adipocytes | 7 | 2012 | 1182 | 0.370 |
Why?
|
| Melanoma-Specific Antigens | 7 | 2021 | 80 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 12 | 12 | 2013 | 462 | 0.370 |
Why?
|
| Antineoplastic Agents | 25 | 2022 | 13655 | 0.360 |
Why?
|
| Immunophenotyping | 10 | 2020 | 1866 | 0.360 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 314 | 0.360 |
Why?
|
| Pathology, Surgical | 5 | 2009 | 155 | 0.350 |
Why?
|
| Time Factors | 24 | 2019 | 40054 | 0.350 |
Why?
|
| Skin Diseases | 6 | 2010 | 1065 | 0.350 |
Why?
|
| Sequence Analysis, RNA | 9 | 2021 | 2011 | 0.350 |
Why?
|
| Histone Acetyltransferases | 1 | 2011 | 336 | 0.340 |
Why?
|
| Cytogenetic Analysis | 9 | 2012 | 295 | 0.340 |
Why?
|
| Sclerosis | 5 | 2014 | 210 | 0.340 |
Why?
|
| Myofibromatosis | 3 | 2002 | 30 | 0.340 |
Why?
|
| Neuroectodermal Tumors | 3 | 2023 | 27 | 0.340 |
Why?
|
| Phenotype | 18 | 2022 | 16331 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 15 | 2023 | 9274 | 0.330 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 1351 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 20 | 2016 | 4751 | 0.330 |
Why?
|
| Prostatic Neoplasms | 3 | 2021 | 11039 | 0.330 |
Why?
|
| DNA Mutational Analysis | 12 | 2018 | 4187 | 0.330 |
Why?
|
| Pericytes | 3 | 2014 | 291 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 7 | 6 | 2014 | 321 | 0.320 |
Why?
|
| Follow-Up Studies | 34 | 2018 | 39004 | 0.320 |
Why?
|
| Giant Cells | 5 | 2008 | 187 | 0.310 |
Why?
|
| Proteoglycans | 1 | 2011 | 834 | 0.310 |
Why?
|
| Blood Vessels | 1 | 2014 | 1124 | 0.310 |
Why?
|
| Choristoma | 5 | 1993 | 213 | 0.310 |
Why?
|
| Fibromatosis, Abdominal | 3 | 2008 | 24 | 0.310 |
Why?
|
| STAT6 Transcription Factor | 2 | 2021 | 199 | 0.310 |
Why?
|
| Gardner Syndrome | 1 | 2007 | 4 | 0.300 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2020 | 1097 | 0.300 |
Why?
|
| Immobilization | 1 | 2008 | 236 | 0.300 |
Why?
|
| Angiomyoma | 2 | 1997 | 12 | 0.300 |
Why?
|
| Joint Diseases | 2 | 2016 | 478 | 0.300 |
Why?
|
| Receptor, trkC | 4 | 2020 | 68 | 0.300 |
Why?
|
| Chondroma | 3 | 2018 | 58 | 0.300 |
Why?
|
| Pleural Neoplasms | 3 | 2017 | 607 | 0.300 |
Why?
|
| Peritoneal Neoplasms | 4 | 2017 | 663 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 16 | 5 | 2010 | 355 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2022 | 2948 | 0.290 |
Why?
|
| Necrosis | 9 | 2023 | 1643 | 0.290 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 8 | 2010 | 293 | 0.290 |
Why?
|
| Neuroendocrine Tumors | 2 | 2023 | 594 | 0.290 |
Why?
|
| Schwann Cells | 1 | 2007 | 195 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2010 | 5522 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 4 | 2021 | 5867 | 0.280 |
Why?
|
| Muscular Diseases | 6 | 2002 | 557 | 0.280 |
Why?
|
| Cyclin B | 2 | 2018 | 108 | 0.280 |
Why?
|
| Pathology | 4 | 2007 | 272 | 0.270 |
Why?
|
| Gingival Neoplasms | 2 | 1999 | 21 | 0.270 |
Why?
|
| Synovitis, Pigmented Villonodular | 3 | 2000 | 34 | 0.270 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2018 | 2028 | 0.270 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2023 | 224 | 0.270 |
Why?
|
| Melanocytes | 4 | 2021 | 515 | 0.270 |
Why?
|
| Disease Progression | 14 | 2018 | 13256 | 0.270 |
Why?
|
| Phosphoproteins | 3 | 2013 | 2440 | 0.260 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 895 | 0.260 |
Why?
|
| Chromosome Disorders | 5 | 2000 | 515 | 0.260 |
Why?
|
| Lymphangioma, Cystic | 1 | 2005 | 34 | 0.260 |
Why?
|
| Review Literature as Topic | 2 | 2015 | 333 | 0.260 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2018 | 171 | 0.260 |
Why?
|
| Medical Oncology | 4 | 2022 | 2235 | 0.260 |
Why?
|
| Facial Neoplasms | 3 | 2007 | 121 | 0.250 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 1596 | 0.250 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 974 | 0.250 |
Why?
|
| Lymphoma | 6 | 2019 | 1873 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2015 | 704 | 0.250 |
Why?
|
| Mobility Limitation | 1 | 2008 | 405 | 0.250 |
Why?
|
| Sarcoma, Kaposi | 3 | 2000 | 370 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2022 | 17400 | 0.240 |
Why?
|
| Fatal Outcome | 9 | 2007 | 1849 | 0.240 |
Why?
|
| Survival Rate | 20 | 2019 | 12773 | 0.240 |
Why?
|
| Mucin-4 | 3 | 2014 | 37 | 0.240 |
Why?
|
| MART-1 Antigen | 4 | 2008 | 64 | 0.240 |
Why?
|
| Muscle, Skeletal | 3 | 2017 | 4933 | 0.240 |
Why?
|
| In Situ Hybridization | 10 | 2016 | 1950 | 0.240 |
Why?
|
| Antigens, CD | 14 | 2010 | 4024 | 0.240 |
Why?
|
| Tongue Neoplasms | 2 | 1999 | 179 | 0.240 |
Why?
|
| ras Proteins | 3 | 2019 | 1060 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 4 | 2022 | 930 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 7 | 2018 | 380 | 0.230 |
Why?
|
| Transcription Factor CHOP | 2 | 2021 | 73 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2022 | 2842 | 0.230 |
Why?
|
| Histiocytic Disorders, Malignant | 2 | 2018 | 16 | 0.230 |
Why?
|
| Cell Proliferation | 12 | 2023 | 10472 | 0.230 |
Why?
|
| Rectal Neoplasms | 2 | 2011 | 1195 | 0.230 |
Why?
|
| Meninges | 4 | 2010 | 190 | 0.230 |
Why?
|
| Chloride Channels | 2 | 2018 | 225 | 0.230 |
Why?
|
| Tropomyosin | 3 | 2018 | 102 | 0.220 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2014 | 281 | 0.220 |
Why?
|
| Tenosynovitis | 2 | 2000 | 57 | 0.220 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2023 | 100 | 0.220 |
Why?
|
| Gene Silencing | 4 | 2019 | 1538 | 0.220 |
Why?
|
| Neoplasms, Nerve Tissue | 2 | 1993 | 23 | 0.220 |
Why?
|
| Splenic Neoplasms | 1 | 2003 | 100 | 0.220 |
Why?
|
| Retrospective Studies | 38 | 2022 | 77098 | 0.220 |
Why?
|
| Vimentin | 10 | 2010 | 261 | 0.210 |
Why?
|
| Histiocytes | 2 | 2021 | 103 | 0.210 |
Why?
|
| Adenomatoid Tumor | 1 | 2022 | 13 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2016 | 3731 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 6 | 2014 | 7276 | 0.210 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2022 | 26 | 0.210 |
Why?
|
| Diploidy | 1 | 2022 | 138 | 0.210 |
Why?
|
| Lymphatic Metastasis | 8 | 2023 | 2906 | 0.210 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2022 | 47 | 0.210 |
Why?
|
| Fibronectins | 3 | 2021 | 723 | 0.200 |
Why?
|
| NFI Transcription Factors | 1 | 2021 | 44 | 0.200 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2001 | 17 | 0.200 |
Why?
|
| Scrotum | 2 | 1992 | 114 | 0.200 |
Why?
|
| Protein Kinase C-delta | 2 | 2015 | 123 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 11 | 2013 | 6171 | 0.200 |
Why?
|
| Base Sequence | 19 | 2014 | 12797 | 0.200 |
Why?
|
| Receptor, trkB | 2 | 2020 | 125 | 0.200 |
Why?
|
| Mechanoreceptors | 2 | 2015 | 186 | 0.200 |
Why?
|
| Chondroblastoma | 2 | 2020 | 50 | 0.200 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2002 | 224 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2020 | 5163 | 0.190 |
Why?
|
| Mesothelioma | 3 | 2017 | 818 | 0.190 |
Why?
|
| Splenic Diseases | 1 | 2001 | 94 | 0.190 |
Why?
|
| Specialty Boards | 1 | 2003 | 227 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 1525 | 0.190 |
Why?
|
| Thiazolidinediones | 6 | 2004 | 476 | 0.190 |
Why?
|
| Lymphatic Diseases | 2 | 2002 | 324 | 0.190 |
Why?
|
| Histiocytosis, Sinus | 2 | 2016 | 47 | 0.190 |
Why?
|
| Subcutaneous Tissue | 3 | 2008 | 135 | 0.190 |
Why?
|
| Neoplasms | 9 | 2023 | 21596 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2020 | 2229 | 0.190 |
Why?
|
| Fibromatosis, Aggressive | 4 | 2008 | 118 | 0.190 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2018 | 870 | 0.180 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 6347 | 0.180 |
Why?
|
| Infant, Newborn | 17 | 2023 | 25575 | 0.180 |
Why?
|
| Tissue Banks | 2 | 2014 | 183 | 0.180 |
Why?
|
| Myosarcoma | 2 | 1998 | 3 | 0.180 |
Why?
|
| Osteosarcoma | 8 | 2019 | 880 | 0.180 |
Why?
|
| MyoD Protein | 4 | 2014 | 151 | 0.180 |
Why?
|
| Angiolipoma | 2 | 1997 | 13 | 0.180 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2017 | 116 | 0.180 |
Why?
|
| Neuroma | 3 | 1990 | 101 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2020 | 11472 | 0.180 |
Why?
|
| Pathology, Molecular | 2 | 2014 | 325 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2018 | 535 | 0.170 |
Why?
|
| Tendons | 4 | 2008 | 548 | 0.170 |
Why?
|
| Ischemia | 1 | 2008 | 1911 | 0.170 |
Why?
|
| von Willebrand Factor | 7 | 2018 | 668 | 0.170 |
Why?
|
| Ribosomal Proteins | 1 | 2001 | 360 | 0.170 |
Why?
|
| Retinal Neoplasms | 1 | 2021 | 144 | 0.170 |
Why?
|
| Anaplasia | 2 | 2009 | 16 | 0.170 |
Why?
|
| Neoplasm Staging | 15 | 2020 | 11001 | 0.170 |
Why?
|
| Vaginal Neoplasms | 1 | 2000 | 106 | 0.170 |
Why?
|
| Axons | 1 | 2007 | 1681 | 0.170 |
Why?
|
| Membrane Glycoproteins | 7 | 2020 | 3769 | 0.170 |
Why?
|
| 14-3-3 Proteins | 1 | 2020 | 214 | 0.170 |
Why?
|
| Lymph Nodes | 7 | 2020 | 3465 | 0.170 |
Why?
|
| Retinoblastoma Protein | 3 | 2012 | 701 | 0.170 |
Why?
|
| Lymphokines | 2 | 2018 | 949 | 0.170 |
Why?
|
| Pharyngeal Neoplasms | 2 | 2006 | 117 | 0.170 |
Why?
|
| Carcinosarcoma | 2 | 1997 | 108 | 0.170 |
Why?
|
| Collagen Type VI | 1 | 2018 | 26 | 0.170 |
Why?
|
| Survival Analysis | 12 | 2017 | 10248 | 0.170 |
Why?
|
| Fingers | 2 | 1994 | 514 | 0.160 |
Why?
|
| Histiocytic Sarcoma | 1 | 2019 | 44 | 0.160 |
Why?
|
| Ganglioneuroma | 2 | 1989 | 57 | 0.160 |
Why?
|
| Retinoblastoma | 1 | 2021 | 318 | 0.160 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 116 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 2012 | 462 | 0.160 |
Why?
|
| Angiomatosis | 3 | 1994 | 49 | 0.160 |
Why?
|
| Polyps | 1 | 2000 | 189 | 0.160 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2018 | 40 | 0.160 |
Why?
|
| Dendritic Cells | 5 | 2001 | 2723 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 2010 | 438 | 0.160 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2002 | 140 | 0.160 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 4 | 2008 | 251 | 0.160 |
Why?
|
| Antigens, Surface | 2 | 2001 | 1663 | 0.160 |
Why?
|
| Hemorrhage | 4 | 2019 | 3461 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2021 | 349 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2018 | 203 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2012 | 403 | 0.150 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 4 | 2007 | 514 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2000 | 253 | 0.150 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2017 | 82 | 0.150 |
Why?
|
| Lipids | 2 | 2000 | 3302 | 0.150 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2020 | 37 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2016 | 1081 | 0.150 |
Why?
|
| Leukemia, B-Cell | 1 | 2017 | 86 | 0.150 |
Why?
|
| Ovarian Cysts | 1 | 2018 | 115 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2018 | 625 | 0.150 |
Why?
|
| Gene Amplification | 6 | 2013 | 1062 | 0.150 |
Why?
|
| Inguinal Canal | 1 | 1997 | 69 | 0.150 |
Why?
|
| Synovial Membrane | 1 | 2000 | 506 | 0.150 |
Why?
|
| Combined Modality Therapy | 11 | 2017 | 8621 | 0.150 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 1997 | 285 | 0.150 |
Why?
|
| Skull Neoplasms | 1 | 2018 | 173 | 0.150 |
Why?
|
| DNA Helicases | 2 | 2020 | 861 | 0.150 |
Why?
|
| Comparative Genomic Hybridization | 4 | 2014 | 496 | 0.150 |
Why?
|
| Gene Dosage | 4 | 2022 | 1251 | 0.140 |
Why?
|
| Receptors, Cell Surface | 3 | 2015 | 2867 | 0.140 |
Why?
|
| Facial Bones | 1 | 2018 | 201 | 0.140 |
Why?
|
| Mutation, Missense | 3 | 2019 | 2556 | 0.140 |
Why?
|
| Molecular Sequence Data | 21 | 2014 | 18112 | 0.140 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 2016 | 13 | 0.140 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2016 | 76 | 0.140 |
Why?
|
| Plasma Cells | 3 | 2011 | 592 | 0.140 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 290 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2018 | 135 | 0.140 |
Why?
|
| Vulva | 2 | 2022 | 87 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 3 | 2010 | 2633 | 0.140 |
Why?
|
| 5-Methylcytosine | 1 | 2017 | 153 | 0.140 |
Why?
|
| Neuroglia | 2 | 1993 | 925 | 0.140 |
Why?
|
| G1 Phase | 1 | 1997 | 415 | 0.140 |
Why?
|
| Neurofibromatoses | 1 | 2020 | 299 | 0.140 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2016 | 23 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 6 | 2002 | 867 | 0.140 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1997 | 286 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6534 | 0.140 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2015 | 35 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 1999 | 374 | 0.140 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2015 | 30 | 0.130 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 1996 | 83 | 0.130 |
Why?
|
| Ploidies | 2 | 2000 | 281 | 0.130 |
Why?
|
| WT1 Proteins | 1 | 2016 | 178 | 0.130 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2016 | 165 | 0.130 |
Why?
|
| Osteoclasts | 3 | 1994 | 729 | 0.130 |
Why?
|
| Thiazoles | 6 | 2010 | 1484 | 0.130 |
Why?
|
| Genes, fos | 1 | 2015 | 183 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2023 | 4029 | 0.130 |
Why?
|
| Age Distribution | 3 | 2011 | 2900 | 0.130 |
Why?
|
| Gene Expression | 10 | 2013 | 7790 | 0.130 |
Why?
|
| RNA, Neoplasm | 5 | 2010 | 768 | 0.130 |
Why?
|
| Germ-Line Mutation | 2 | 2023 | 1786 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1052 | 0.130 |
Why?
|
| Inflammation | 7 | 2023 | 10578 | 0.130 |
Why?
|
| Ovarian Neoplasms | 4 | 2017 | 4823 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2022 | 2906 | 0.130 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 40 | 0.130 |
Why?
|
| Diagnostic Errors | 5 | 2010 | 1255 | 0.130 |
Why?
|
| Paranasal Sinuses | 1 | 1997 | 249 | 0.130 |
Why?
|
| Cyclins | 3 | 2007 | 601 | 0.120 |
Why?
|
| Nasopharynx | 1 | 1997 | 379 | 0.120 |
Why?
|
| Hemangioma, Capillary | 1 | 1995 | 61 | 0.120 |
Why?
|
| Ribonucleoproteins | 1 | 1997 | 381 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 1431 | 0.120 |
Why?
|
| Trisomy | 4 | 2000 | 266 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 874 | 0.120 |
Why?
|
| Ossification, Heterotopic | 2 | 1996 | 239 | 0.120 |
Why?
|
| Connective Tissue Diseases | 1 | 1997 | 264 | 0.120 |
Why?
|
| Chromogranins | 2 | 2012 | 163 | 0.120 |
Why?
|
| Fibroadenoma | 1 | 1994 | 43 | 0.120 |
Why?
|
| Zinc Fingers | 3 | 2010 | 585 | 0.120 |
Why?
|
| Gene Deletion | 4 | 2014 | 2751 | 0.120 |
Why?
|
| Decidua | 1 | 1994 | 86 | 0.120 |
Why?
|
| Sensitivity and Specificity | 10 | 2021 | 14720 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2014 | 2038 | 0.120 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cell Line, Tumor | 8 | 2020 | 16665 | 0.120 |
Why?
|
| Lymphangiomyoma | 1 | 1993 | 10 | 0.120 |
Why?
|
| Sulfonamides | 2 | 2014 | 1932 | 0.120 |
Why?
|
| Knee Joint | 3 | 2016 | 1679 | 0.120 |
Why?
|
| Meningioma | 3 | 1998 | 1209 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 5 | 1999 | 1599 | 0.110 |
Why?
|
| Myosins | 3 | 2005 | 409 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 197 | 0.110 |
Why?
|
| Histocytochemistry | 5 | 2000 | 718 | 0.110 |
Why?
|
| Leukocyte Count | 3 | 2012 | 1583 | 0.110 |
Why?
|
| Brugia pahangi | 1 | 1992 | 1 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2005 | 713 | 0.110 |
Why?
|
| Cyclin D | 2 | 2007 | 71 | 0.110 |
Why?
|
| Filariasis | 1 | 1992 | 28 | 0.110 |
Why?
|
| Muscles | 3 | 2018 | 1617 | 0.110 |
Why?
|
| Antibodies, Helminth | 1 | 1992 | 50 | 0.110 |
Why?
|
| Prostate | 1 | 2021 | 1764 | 0.110 |
Why?
|
| Cyclin D1 | 1 | 2015 | 462 | 0.110 |
Why?
|
| Antigens, Helminth | 1 | 1992 | 64 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2012 | 202 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 2 | 2009 | 299 | 0.110 |
Why?
|
| Dystrophin | 1 | 2014 | 285 | 0.110 |
Why?
|
| Hedgehog Proteins | 2 | 2018 | 781 | 0.110 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 101 | 0.110 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2014 | 152 | 0.110 |
Why?
|
| Penile Neoplasms | 3 | 1996 | 159 | 0.110 |
Why?
|
| Spermatic Cord | 1 | 1992 | 25 | 0.110 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2005 | 524 | 0.110 |
Why?
|
| Ki-67 Antigen | 3 | 2001 | 644 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2011 | 366 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 8 | 2016 | 3920 | 0.110 |
Why?
|
| Receptors, AMPA | 1 | 2014 | 331 | 0.100 |
Why?
|
| Myoglobin | 2 | 2005 | 160 | 0.100 |
Why?
|
| Endothelium, Vascular | 6 | 2002 | 4455 | 0.100 |
Why?
|
| Xanthomatosis | 1 | 1991 | 32 | 0.100 |
Why?
|
| Hematoma | 1 | 1997 | 755 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7873 | 0.100 |
Why?
|
| Staining and Labeling | 4 | 2004 | 1099 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2019 | 5062 | 0.100 |
Why?
|
| Choroid Plexus Neoplasms | 2 | 2012 | 43 | 0.100 |
Why?
|
| Salivary Glands | 1 | 2013 | 228 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2004 | 1769 | 0.100 |
Why?
|
| Muscular Dystrophies | 1 | 2014 | 393 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 2011 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2014 | 319 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2008 | 1725 | 0.100 |
Why?
|
| Protein Kinase C | 2 | 2008 | 1227 | 0.100 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 399 | 0.100 |
Why?
|
| Thigh | 2 | 1999 | 247 | 0.100 |
Why?
|
| Intestine, Small | 2 | 1995 | 1243 | 0.100 |
Why?
|
| Interphase | 1 | 2011 | 224 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2017 | 603 | 0.100 |
Why?
|
| Peripheral Nerves | 1 | 1995 | 474 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15244 | 0.100 |
Why?
|
| Hemangioma, Cavernous | 1 | 1991 | 110 | 0.100 |
Why?
|
| Monosomy | 2 | 2004 | 54 | 0.100 |
Why?
|
| Bone Cysts, Aneurysmal | 2 | 2002 | 73 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 694 | 0.090 |
Why?
|
| Neoplasms, Adipose Tissue | 2 | 2003 | 15 | 0.090 |
Why?
|
| Molecular Biology | 3 | 2023 | 595 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2016 | 503 | 0.090 |
Why?
|
| Cohort Studies | 8 | 2020 | 40450 | 0.090 |
Why?
|
| Dystonia | 1 | 2014 | 363 | 0.090 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 1990 | 11 | 0.090 |
Why?
|
| Phyllodes Tumor | 1 | 1990 | 53 | 0.090 |
Why?
|
| Nevus of Ota | 1 | 2009 | 4 | 0.090 |
Why?
|
| Metaplasia | 3 | 1998 | 313 | 0.090 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2005 | 106 | 0.090 |
Why?
|
| Pacinian Corpuscles | 1 | 1989 | 3 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 792 | 0.090 |
Why?
|
| Homozygote | 2 | 2014 | 1777 | 0.090 |
Why?
|
| Exons | 7 | 2008 | 2431 | 0.090 |
Why?
|
| United States | 13 | 2020 | 69693 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 1998 | 2542 | 0.090 |
Why?
|
| Societies, Medical | 3 | 2019 | 3740 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2009 | 22 | 0.090 |
Why?
|
| Genes, jun | 1 | 2009 | 71 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3455 | 0.090 |
Why?
|
| Genotype | 5 | 2017 | 12946 | 0.090 |
Why?
|
| Nuclear Envelope | 1 | 2011 | 172 | 0.090 |
Why?
|
| Cell Division | 9 | 2004 | 4564 | 0.090 |
Why?
|
| Carcinoma, Embryonal | 1 | 2009 | 38 | 0.090 |
Why?
|
| Lymphocytes | 3 | 2020 | 2614 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 1059 | 0.090 |
Why?
|
| Flow Cytometry | 4 | 2002 | 5975 | 0.090 |
Why?
|
| Nervous System Neoplasms | 1 | 1989 | 91 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 1640 | 0.080 |
Why?
|
| Thymoma | 1 | 1990 | 186 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 7770 | 0.080 |
Why?
|
| Chromosome Banding | 5 | 2014 | 278 | 0.080 |
Why?
|
| Gene Expression Profiling | 8 | 2016 | 9410 | 0.080 |
Why?
|
| Immunoblotting | 2 | 2020 | 1683 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3585 | 0.080 |
Why?
|
| Chemokine CXCL13 | 1 | 2008 | 54 | 0.080 |
Why?
|
| Thoracic Wall | 1 | 2010 | 201 | 0.080 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2008 | 53 | 0.080 |
Why?
|
| Chromans | 4 | 2004 | 122 | 0.080 |
Why?
|
| Warfarin | 1 | 2017 | 1493 | 0.080 |
Why?
|
| Stem Cell Factor | 1 | 2009 | 219 | 0.080 |
Why?
|
| Diagnosis | 1 | 2009 | 154 | 0.080 |
Why?
|
| Cytogenetics | 3 | 1998 | 203 | 0.080 |
Why?
|
| Proteus Syndrome | 1 | 2007 | 14 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2022 | 53187 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2013 | 554 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1792 | 0.080 |
Why?
|
| Cartilage | 3 | 1996 | 818 | 0.080 |
Why?
|
| Onions | 1 | 2007 | 7 | 0.080 |
Why?
|
| Histological Techniques | 3 | 2015 | 198 | 0.080 |
Why?
|
| Radiography | 4 | 2010 | 7010 | 0.080 |
Why?
|
| Mesentery | 1 | 2008 | 205 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 20 | 3 | 2014 | 133 | 0.080 |
Why?
|
| Chromosome Mapping | 7 | 2010 | 4742 | 0.080 |
Why?
|
| Flowers | 1 | 2007 | 28 | 0.080 |
Why?
|
| Tarsal Tunnel Syndrome | 1 | 1987 | 9 | 0.080 |
Why?
|
| Insect Control | 1 | 2007 | 28 | 0.080 |
Why?
|
| Sweat Gland Neoplasms | 3 | 1997 | 108 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 987 | 0.080 |
Why?
|
| Bone and Bones | 1 | 1998 | 2575 | 0.080 |
Why?
|
| Transcription, Genetic | 6 | 2014 | 7721 | 0.080 |
Why?
|
| DNA, Complementary | 5 | 2002 | 2049 | 0.080 |
Why?
|
| Teratoma | 1 | 2010 | 387 | 0.080 |
Why?
|
| Vascular Malformations | 1 | 2013 | 450 | 0.070 |
Why?
|
| Microfilament Proteins | 2 | 2008 | 1152 | 0.070 |
Why?
|
| Tibial Nerve | 1 | 1987 | 57 | 0.070 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 1997 | 335 | 0.070 |
Why?
|
| Scleroderma, Systemic | 1 | 2011 | 313 | 0.070 |
Why?
|
| Genetic Markers | 3 | 2011 | 2633 | 0.070 |
Why?
|
| Mesoderm | 2 | 2002 | 686 | 0.070 |
Why?
|
| Signal Transduction | 10 | 2018 | 23387 | 0.070 |
Why?
|
| Consensus | 3 | 2022 | 2935 | 0.070 |
Why?
|
| Pheromones | 1 | 2007 | 98 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 19862 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 12344 | 0.070 |
Why?
|
| Mice | 17 | 2018 | 81045 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2015 | 2500 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3123 | 0.070 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2009 | 210 | 0.070 |
Why?
|
| Internship and Residency | 2 | 2007 | 5774 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2014 | 537 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2008 | 363 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 2502 | 0.070 |
Why?
|
| Chordoma | 3 | 2002 | 359 | 0.070 |
Why?
|
| Hemosiderin | 1 | 2006 | 43 | 0.070 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 90 | 0.070 |
Why?
|
| Urethral Neoplasms | 1 | 2006 | 40 | 0.070 |
Why?
|
| Reference Standards | 2 | 2008 | 1020 | 0.070 |
Why?
|
| Herpesvirus 8, Human | 2 | 2013 | 258 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4249 | 0.070 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 553 | 0.070 |
Why?
|
| Deep Brain Stimulation | 1 | 2014 | 746 | 0.070 |
Why?
|
| RNA, Messenger | 10 | 2014 | 13029 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2018 | 318 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 1114 | 0.070 |
Why?
|
| Phosphorylation | 9 | 2010 | 8436 | 0.070 |
Why?
|
| Ring Chromosomes | 2 | 2003 | 22 | 0.070 |
Why?
|
| Positron-Emission Tomography | 4 | 2009 | 6259 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 1999 | 657 | 0.070 |
Why?
|
| Ulcer | 1 | 1987 | 209 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 692 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 602 | 0.070 |
Why?
|
| Thymus Gland | 1 | 1990 | 1264 | 0.070 |
Why?
|
| Genes, erbB-1 | 1 | 2006 | 161 | 0.070 |
Why?
|
| Chromosome Deletion | 4 | 2014 | 1400 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2011 | 2295 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1940 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 1213 | 0.070 |
Why?
|
| France | 2 | 2021 | 517 | 0.070 |
Why?
|
| DNA Primers | 4 | 2015 | 2892 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2002 | 3760 | 0.060 |
Why?
|
| Cell Movement | 2 | 2014 | 5212 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2007 | 264 | 0.060 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 2004 | 52 | 0.060 |
Why?
|
| Incidence | 6 | 2021 | 20928 | 0.060 |
Why?
|
| Animals | 27 | 2020 | 168561 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 10163 | 0.060 |
Why?
|
| Collagen | 4 | 2003 | 2684 | 0.060 |
Why?
|
| Subcutaneous Fat | 1 | 2008 | 391 | 0.060 |
Why?
|
| Tuberous Sclerosis | 2 | 2011 | 1029 | 0.060 |
Why?
|
| Vascular Diseases | 3 | 2003 | 1155 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2006 | 213 | 0.060 |
Why?
|
| Paraganglioma | 1 | 2006 | 143 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2009 | 3689 | 0.060 |
Why?
|
| Up-Regulation | 4 | 2016 | 4211 | 0.060 |
Why?
|
| Adipose Tissue | 4 | 2013 | 3278 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 9 | 2010 | 6313 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2023 | 91 | 0.060 |
Why?
|
| Brain Neoplasms | 3 | 2002 | 8829 | 0.060 |
Why?
|
| Cytoplasm | 4 | 1997 | 1539 | 0.060 |
Why?
|
| X Chromosome | 3 | 2001 | 815 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2004 | 664 | 0.060 |
Why?
|
| Veterans | 1 | 2017 | 2513 | 0.060 |
Why?
|
| Veins | 1 | 1988 | 769 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1999 | 3695 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2011 | 4554 | 0.060 |
Why?
|
| Genes, APC | 1 | 2023 | 159 | 0.060 |
Why?
|
| Receptor, Insulin | 1 | 2007 | 846 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3639 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 3800 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 1040 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2023 | 188 | 0.050 |
Why?
|
| Enzyme Activation | 5 | 2011 | 3701 | 0.050 |
Why?
|
| Arteries | 1 | 1988 | 1118 | 0.050 |
Why?
|
| Amino Acid Sequence | 9 | 2014 | 13814 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2020 | 905 | 0.050 |
Why?
|
| Receptors, Growth Factor | 2 | 2001 | 334 | 0.050 |
Why?
|
| Chondromatosis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 1402 | 0.050 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2022 | 27 | 0.050 |
Why?
|
| Zebrafish | 4 | 2011 | 2990 | 0.050 |
Why?
|
| Sirolimus | 1 | 2010 | 1562 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2007 | 692 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2022 | 141 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 1860 | 0.050 |
Why?
|
| Hand | 1 | 2007 | 882 | 0.050 |
Why?
|
| SOXD Transcription Factors | 1 | 2022 | 47 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2021 | 599 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 3 | 2018 | 874 | 0.050 |
Why?
|
| Neutrophils | 2 | 2012 | 3711 | 0.050 |
Why?
|
| Microsurgery | 1 | 1988 | 796 | 0.050 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2002 | 104 | 0.050 |
Why?
|
| Multigene Family | 2 | 1996 | 1102 | 0.050 |
Why?
|
| Computational Biology | 3 | 2011 | 3518 | 0.050 |
Why?
|
| Activin Receptors, Type I | 1 | 2002 | 142 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5425 | 0.050 |
Why?
|
| Seminoma | 1 | 2023 | 136 | 0.050 |
Why?
|
| Activin Receptors, Type II | 1 | 2002 | 127 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 5 | 2011 | 4801 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2015 | 4282 | 0.050 |
Why?
|
| Risk | 1 | 2014 | 9679 | 0.050 |
Why?
|
| Chromosome Breakage | 3 | 2012 | 173 | 0.050 |
Why?
|
| Genomics | 4 | 2023 | 5692 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 420 | 0.050 |
Why?
|
| Factor XIII | 1 | 2001 | 59 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2006 | 804 | 0.050 |
Why?
|
| Genome | 4 | 2006 | 1803 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 1740 | 0.050 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 1994 | 135 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 2274 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2021 | 97 | 0.050 |
Why?
|
| Eosinophilia | 2 | 1984 | 531 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2005 | 4465 | 0.050 |
Why?
|
| Exophthalmos | 1 | 2001 | 96 | 0.050 |
Why?
|
| Wilms Tumor | 2 | 2015 | 368 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2021 | 3678 | 0.050 |
Why?
|
| Receptor, TIE-2 | 1 | 2021 | 178 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 2505 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 1984 | 332 | 0.050 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2000 | 54 | 0.050 |
Why?
|
| Cloning, Molecular | 4 | 2002 | 4322 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2020 | 42 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2020 | 53 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2006 | 1144 | 0.050 |
Why?
|
| Appendix | 1 | 2021 | 110 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2001 | 277 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1998 | 1504 | 0.050 |
Why?
|
| Cell Nucleolus | 2 | 1997 | 166 | 0.050 |
Why?
|
| Foam Cells | 1 | 2000 | 71 | 0.050 |
Why?
|
| Cell Cycle Proteins | 3 | 2018 | 3444 | 0.050 |
Why?
|
| Cell Cycle | 3 | 2011 | 2964 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2018 | 2107 | 0.040 |
Why?
|
| Indomethacin | 1 | 2000 | 331 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2009 | 2013 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2014 | 20086 | 0.040 |
Why?
|
| Captopril | 1 | 2000 | 272 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2007 | 742 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 250 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 1617 | 0.040 |
Why?
|
| Loss of Heterozygosity | 2 | 2015 | 678 | 0.040 |
Why?
|
| Viscera | 1 | 2020 | 139 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2008 | 2616 | 0.040 |
Why?
|
| Genetic Techniques | 2 | 2001 | 435 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 104 | 0.040 |
Why?
|
| England | 2 | 1997 | 523 | 0.040 |
Why?
|
| Certification | 1 | 2003 | 423 | 0.040 |
Why?
|
| Chromatin | 2 | 2022 | 2917 | 0.040 |
Why?
|
| Thrombospondin 1 | 1 | 2001 | 250 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 772 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2022 | 530 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1999 | 1379 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2020 | 330 | 0.040 |
Why?
|
| Laminin | 3 | 2004 | 418 | 0.040 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 1999 | 67 | 0.040 |
Why?
|
| Rabbits | 2 | 2020 | 4886 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2005 | 3770 | 0.040 |
Why?
|
| SOXE Transcription Factors | 1 | 2018 | 57 | 0.040 |
Why?
|
| Chromosomes, Human | 2 | 2012 | 457 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2011 | 5180 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2001 | 507 | 0.040 |
Why?
|
| Endothelium, Lymphatic | 1 | 1998 | 58 | 0.040 |
Why?
|
| Losartan | 1 | 2000 | 298 | 0.040 |
Why?
|
| Receptors, Complement 3b | 1 | 2018 | 145 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3584 | 0.040 |
Why?
|
| Factor VIII | 2 | 1997 | 348 | 0.040 |
Why?
|
| Communication | 2 | 2009 | 3728 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 694 | 0.040 |
Why?
|
| Boston | 2 | 2021 | 9305 | 0.040 |
Why?
|
| Haploidy | 1 | 1998 | 136 | 0.040 |
Why?
|
| Neuroblastoma | 2 | 2015 | 1225 | 0.040 |
Why?
|
| Reticulin | 1 | 1997 | 21 | 0.040 |
Why?
|
| Septins | 1 | 2018 | 54 | 0.040 |
Why?
|
| Remission Induction | 2 | 2020 | 2384 | 0.040 |
Why?
|
| Japan | 1 | 2002 | 1360 | 0.040 |
Why?
|
| Acrospiroma | 1 | 1997 | 13 | 0.040 |
Why?
|
| Breast | 1 | 2007 | 1958 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1998 | 192 | 0.040 |
Why?
|
| Somatostatin | 1 | 1999 | 459 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 552 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 1997 | 70 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2014 | 35342 | 0.040 |
Why?
|
| Genes | 3 | 2001 | 1892 | 0.040 |
Why?
|
| Jews | 1 | 2019 | 385 | 0.040 |
Why?
|
| Medical Records | 1 | 2003 | 1413 | 0.040 |
Why?
|
| Paired Box Transcription Factors | 1 | 2018 | 215 | 0.040 |
Why?
|
| California | 1 | 2021 | 1400 | 0.040 |
Why?
|
| Muscle Cells | 1 | 2018 | 196 | 0.040 |
Why?
|
| Mucins | 2 | 2012 | 564 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 847 | 0.040 |
Why?
|
| Vagina | 1 | 2022 | 825 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 376 | 0.040 |
Why?
|
| Retinoids | 1 | 1997 | 96 | 0.040 |
Why?
|
| Linoleic Acid | 1 | 1997 | 157 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 841 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 595 | 0.040 |
Why?
|
| Apoptosis | 6 | 2011 | 9715 | 0.040 |
Why?
|
| Lipid Metabolism | 3 | 2000 | 1887 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2004 | 1151 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1997 | 300 | 0.030 |
Why?
|
| Diaphragm | 1 | 1998 | 347 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2018 | 1094 | 0.030 |
Why?
|
| Medical Audit | 1 | 1997 | 467 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 578 | 0.030 |
Why?
|
| Leg | 3 | 1999 | 1110 | 0.030 |
Why?
|
| Microcirculation | 1 | 2001 | 1285 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1997 | 232 | 0.030 |
Why?
|
| Ligands | 5 | 2002 | 3293 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 670 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 1997 | 455 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1997 | 363 | 0.030 |
Why?
|
| Recurrence | 3 | 2012 | 8333 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1997 | 402 | 0.030 |
Why?
|
| Microscopy | 2 | 1991 | 903 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 577 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2000 | 484 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 569 | 0.030 |
Why?
|
| Infarction | 1 | 2017 | 243 | 0.030 |
Why?
|
| Clone Cells | 3 | 2007 | 1692 | 0.030 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2015 | 25 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1999 | 512 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2885 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1992 | 1801 | 0.030 |
Why?
|
| Phosphatidylcholines | 3 | 2002 | 411 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1434 | 0.030 |
Why?
|
| Skin Pigmentation | 1 | 1997 | 281 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2022 | 1093 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 1999 | 435 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 1144 | 0.030 |
Why?
|
| Genes, DCC | 1 | 1994 | 12 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2017 | 659 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 219 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2077 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2007 | 3527 | 0.030 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2014 | 44 | 0.030 |
Why?
|
| Lamin Type A | 1 | 2015 | 190 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2002 | 1581 | 0.030 |
Why?
|
| Scalp | 1 | 1997 | 380 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 2203 | 0.030 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1994 | 76 | 0.030 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2014 | 25 | 0.030 |
Why?
|
| Mediator Complex | 1 | 2014 | 109 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 241 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2009 | 2658 | 0.030 |
Why?
|
| Intermediate Filaments | 2 | 1993 | 175 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2000 | 848 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 2 | 2007 | 320 | 0.030 |
Why?
|
| Phospholipids | 1 | 1997 | 781 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2015 | 353 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 435 | 0.030 |
Why?
|
| Bone Diseases | 1 | 1997 | 416 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2004 | 3502 | 0.030 |
Why?
|
| Doxorubicin | 3 | 2008 | 2215 | 0.030 |
Why?
|
| Shoulder | 1 | 1995 | 299 | 0.030 |
Why?
|
| Rickettsia Infections | 1 | 1993 | 9 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2004 | 8925 | 0.030 |
Why?
|
| Social Support | 1 | 2023 | 2117 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2002 | 3510 | 0.030 |
Why?
|
| Keloid | 1 | 1993 | 50 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21719 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 1676 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 1994 | 279 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 413 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 1680 | 0.030 |
Why?
|
| Nucleolus Organizer Region | 1 | 1992 | 26 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1996 | 1183 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1086 | 0.030 |
Why?
|
| Metaphase | 1 | 2012 | 151 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2018 | 1073 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2010 | 2713 | 0.030 |
Why?
|
| Ileal Neoplasms | 1 | 1991 | 21 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2012 | 98 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2012 | 172 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2747 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2018 | 14554 | 0.030 |
Why?
|
| Genital Diseases, Male | 1 | 1992 | 83 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 15494 | 0.030 |
Why?
|
| Gene Order | 1 | 2012 | 176 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 72145 | 0.030 |
Why?
|
| Erythromycin | 1 | 1991 | 120 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2022 | 23320 | 0.030 |
Why?
|
| Arm | 1 | 1995 | 589 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 1995 | 688 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 1993 | 286 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1991 | 98 | 0.030 |
Why?
|
| Phosphorylcholine | 2 | 2002 | 162 | 0.030 |
Why?
|
| Monocytes | 1 | 2001 | 2593 | 0.020 |
Why?
|
| Glioma | 1 | 1986 | 3388 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 4771 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2007 | 4681 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 299 | 0.020 |
Why?
|
| Age Factors | 5 | 2006 | 18355 | 0.020 |
Why?
|
| Elbow | 1 | 1991 | 136 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 375 | 0.020 |
Why?
|
| Larva | 1 | 1992 | 517 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2014 | 766 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2002 | 2145 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1999 | 1837 | 0.020 |
Why?
|
| Reoperation | 2 | 1997 | 4200 | 0.020 |
Why?
|
| Antibodies | 2 | 1997 | 2459 | 0.020 |
Why?
|
| Adenoma, Sweat Gland | 1 | 1990 | 18 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2000 | 2043 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2001 | 2837 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2010 | 126 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2007 | 1526 | 0.020 |
Why?
|
| Indazoles | 1 | 2012 | 287 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 9735 | 0.020 |
Why?
|
| CHO Cells | 2 | 2003 | 1407 | 0.020 |
Why?
|
| Genes, Retinoblastoma | 1 | 1990 | 136 | 0.020 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 1989 | 5 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 2276 | 0.020 |
Why?
|
| Glucuronidase | 1 | 1991 | 207 | 0.020 |
Why?
|
| Liver | 2 | 2004 | 7470 | 0.020 |
Why?
|
| International Cooperation | 2 | 2011 | 1421 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 1284 | 0.020 |
Why?
|
| Fibrosis | 1 | 2017 | 2026 | 0.020 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 1413 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1990 | 45 | 0.020 |
Why?
|
| Animals, Genetically Modified | 2 | 2005 | 1546 | 0.020 |
Why?
|
| Mast Cells | 1 | 1997 | 1544 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2011 | 2938 | 0.020 |
Why?
|
| Eosinophils | 2 | 1984 | 953 | 0.020 |
Why?
|
| Tyrosine | 2 | 2007 | 1460 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2020 | 2941 | 0.020 |
Why?
|
| Cricetinae | 2 | 2003 | 2471 | 0.020 |
Why?
|
| Zebrafish Proteins | 1 | 2016 | 1004 | 0.020 |
Why?
|
| Nipples | 1 | 1991 | 216 | 0.020 |
Why?
|
| Industry | 1 | 2011 | 365 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2011 | 317 | 0.020 |
Why?
|
| Double-Blind Method | 3 | 2012 | 12017 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1989 | 199 | 0.020 |
Why?
|
| Macrophages | 2 | 1995 | 5655 | 0.020 |
Why?
|
| Penis | 1 | 1990 | 216 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Receptors, CXCR5 | 1 | 2008 | 92 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1997 | 2245 | 0.020 |
Why?
|
| Platelet Count | 1 | 2011 | 780 | 0.020 |
Why?
|
| Research Design | 1 | 2004 | 5979 | 0.020 |
Why?
|
| Factor VII | 1 | 1988 | 139 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 2 | 2004 | 5249 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 3504 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2010 | 464 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2008 | 193 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2011 | 723 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 1650 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 6382 | 0.020 |
Why?
|
| Keratitis, Dendritic | 1 | 1987 | 35 | 0.020 |
Why?
|
| Melanins | 1 | 2009 | 288 | 0.020 |
Why?
|
| Endothelium | 1 | 2010 | 778 | 0.020 |
Why?
|
| Down Syndrome | 1 | 1996 | 880 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1782 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1987 | 124 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2007 | 158 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 201 | 0.020 |
Why?
|
| Femoral Vein | 1 | 1988 | 159 | 0.020 |
Why?
|
| Age of Onset | 1 | 2014 | 3266 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1994 | 933 | 0.020 |
Why?
|
| Cystadenoma | 1 | 1987 | 84 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 1993 | 1363 | 0.020 |
Why?
|
| Vinblastine | 1 | 2008 | 490 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 319 | 0.020 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 155 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 5872 | 0.020 |
Why?
|
| Aminosalicylic Acid | 1 | 1986 | 21 | 0.020 |
Why?
|
| New Zealand | 1 | 2007 | 357 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 2030 | 0.020 |
Why?
|
| Acyclovir | 1 | 1987 | 272 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3557 | 0.020 |
Why?
|
| Neck | 1 | 1990 | 693 | 0.020 |
Why?
|
| Malawi | 1 | 1987 | 281 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 1991 | 1159 | 0.020 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1985 | 20 | 0.020 |
Why?
|
| Carotid Body Tumor | 1 | 2006 | 32 | 0.020 |
Why?
|
| Myogenin | 2 | 1998 | 58 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 1873 | 0.020 |
Why?
|
| Sex Factors | 3 | 2006 | 10392 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1985 | 149 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 1986 | 184 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1991 | 1144 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2007 | 271 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 2000 | 803 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 3862 | 0.020 |
Why?
|
| Muramidase | 1 | 1985 | 174 | 0.020 |
Why?
|
| HIV Infections | 1 | 1991 | 16678 | 0.020 |
Why?
|
| Career Choice | 1 | 2011 | 743 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2018 | 5095 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 977 | 0.020 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2004 | 22 | 0.020 |
Why?
|
| Albumins | 1 | 2008 | 568 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2007 | 563 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2000 | 8541 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 390 | 0.020 |
Why?
|
| Artificial Gene Fusion | 1 | 2004 | 57 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 849 | 0.020 |
Why?
|
| Keratoacanthoma | 1 | 1984 | 32 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1997 | 2400 | 0.020 |
Why?
|
| Aging | 1 | 2003 | 8626 | 0.020 |
Why?
|
| History, 18th Century | 1 | 2004 | 214 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 18006 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2010 | 1459 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1987 | 466 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2003 | 3471 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1987 | 802 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2009 | 2615 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 625 | 0.010 |
Why?
|
| Femoral Artery | 1 | 1988 | 843 | 0.010 |
Why?
|
| Multiprotein Complexes | 1 | 2010 | 1119 | 0.010 |
Why?
|
| Methylation | 1 | 2006 | 1107 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3139 | 0.010 |
Why?
|
| Advisory Committees | 1 | 2007 | 773 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7901 | 0.010 |
Why?
|
| Antigens | 1 | 1988 | 1462 | 0.010 |
Why?
|
| Immunoassay | 1 | 1986 | 752 | 0.010 |
Why?
|
| Pyridones | 1 | 2007 | 712 | 0.010 |
Why?
|
| Restriction Mapping | 2 | 1994 | 878 | 0.010 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 1008 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 3001 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2002 | 155 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 891 | 0.010 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2002 | 202 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2010 | 3913 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 627 | 0.010 |
Why?
|
| Osteochondroma | 1 | 2002 | 47 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 4 | 2007 | 21821 | 0.010 |
Why?
|
| Oncogenes | 2 | 2003 | 1263 | 0.010 |
Why?
|
| DNA Replication | 1 | 1988 | 1397 | 0.010 |
Why?
|
| Lung | 3 | 1999 | 9826 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1992 | 8300 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1683 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 4929 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2001 | 69 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 1009 | 0.010 |
Why?
|
| Nevus, Blue | 1 | 2001 | 38 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 1241 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3439 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 1101 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 1992 | 283 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2001 | 245 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 1952 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2001 | 374 | 0.010 |
Why?
|
| Employment | 1 | 2007 | 1124 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 1723 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 950 | 0.010 |
Why?
|
| Abdomen | 1 | 1986 | 1107 | 0.010 |
Why?
|
| Back | 1 | 1999 | 66 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1991 | 1581 | 0.010 |
Why?
|
| Exercise Test | 1 | 1987 | 2075 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1999 | 118 | 0.010 |
Why?
|
| Receptors, OX40 | 1 | 1999 | 43 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 1185 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2271 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 3766 | 0.010 |
Why?
|
| High Mobility Group Proteins | 1 | 2000 | 187 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 2699 | 0.010 |
Why?
|
| Enzymes | 1 | 2001 | 266 | 0.010 |
Why?
|
| Public Sector | 1 | 2001 | 264 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 1086 | 0.010 |
Why?
|
| Polysaccharides | 1 | 1986 | 1051 | 0.010 |
Why?
|
| Octreotide | 1 | 1999 | 145 | 0.010 |
Why?
|
| Primidone | 1 | 1978 | 10 | 0.010 |
Why?
|
| Sequence Alignment | 2 | 1995 | 2257 | 0.010 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1984 | 545 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 1937 | 0.010 |
Why?
|
| Whole-Body Counting | 1 | 1998 | 35 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2007 | 2485 | 0.010 |
Why?
|
| Kidney | 1 | 1994 | 7167 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 1351 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 1076 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 1998 | 118 | 0.010 |
Why?
|
| Pregnancy | 1 | 2000 | 29087 | 0.010 |
Why?
|
| Private Sector | 1 | 2001 | 390 | 0.010 |
Why?
|
| Alleles | 2 | 2005 | 6931 | 0.010 |
Why?
|
| Phenobarbital | 1 | 1978 | 192 | 0.010 |
Why?
|
| Organ Specificity | 2 | 1993 | 2003 | 0.010 |
Why?
|
| Data Collection | 1 | 2007 | 3339 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 1988 | 1527 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 2890 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1997 | 230 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1997 | 93 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2004 | 1095 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1998 | 587 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10943 | 0.010 |
Why?
|
| Registries | 2 | 2008 | 8077 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2001 | 1263 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2000 | 1589 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1997 | 323 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 3923 | 0.010 |
Why?
|
| Vacuoles | 1 | 1997 | 230 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 670 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 494 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2001 | 704 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10372 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2004 | 1483 | 0.010 |
Why?
|
| Heart Rate | 1 | 1987 | 4091 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2714 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 24265 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 15530 | 0.010 |
Why?
|
| Contractile Proteins | 1 | 1997 | 246 | 0.010 |
Why?
|
| Scapula | 1 | 1997 | 162 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13403 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1988 | 2099 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2000 | 1458 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1998 | 981 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 1661 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-gamma | 1 | 1995 | 10 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 5892 | 0.010 |
Why?
|
| Muridae | 1 | 1995 | 61 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 13853 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 1679 | 0.010 |
Why?
|
| DNA | 2 | 2004 | 7289 | 0.010 |
Why?
|
| Homeostasis | 1 | 2006 | 3335 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 1995 | 67 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1998 | 647 | 0.010 |
Why?
|
| Flavonoids | 1 | 1998 | 443 | 0.010 |
Why?
|
| Mesna | 1 | 1994 | 66 | 0.010 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 1994 | 43 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1994 | 118 | 0.010 |
Why?
|
| Proteins | 1 | 2010 | 6096 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 1995 | 170 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1107 | 0.010 |
Why?
|
| Pseudogenes | 1 | 1994 | 113 | 0.010 |
Why?
|
| Heart | 1 | 1987 | 4462 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12242 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1994 | 225 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1997 | 926 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 3493 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 3847 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1995 | 791 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 2126 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1999 | 1423 | 0.010 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1993 | 293 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 6754 | 0.010 |
Why?
|
| Silver Staining | 1 | 1992 | 64 | 0.010 |
Why?
|
| Myogenic Regulatory Factor 5 | 1 | 1991 | 25 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1992 | 172 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 2450 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1995 | 1866 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 1994 | 504 | 0.010 |
Why?
|
| E-Selectin | 1 | 1993 | 579 | 0.010 |
Why?
|
| Triglycerides | 1 | 1999 | 2450 | 0.010 |
Why?
|
| P-Selectin | 1 | 1993 | 600 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 707 | 0.010 |
Why?
|
| Fetus | 1 | 1998 | 1879 | 0.010 |
Why?
|
| Femur | 1 | 1997 | 1297 | 0.010 |
Why?
|
| Insulin | 1 | 2004 | 6575 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1993 | 1155 | 0.010 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 1988 | 32 | 0.010 |
Why?
|
| Host Cell Factor C1 | 1 | 1988 | 31 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 2623 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1994 | 2422 | 0.010 |
Why?
|
| Endocrine System Diseases | 1 | 1990 | 248 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 9581 | 0.000 |
Why?
|
| Cineradiography | 1 | 1987 | 24 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 5519 | 0.000 |
Why?
|
| Phosphonoacetic Acid | 1 | 1987 | 55 | 0.000 |
Why?
|
| Suppuration | 1 | 1987 | 56 | 0.000 |
Why?
|
| Technetium | 1 | 1987 | 334 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2002 | 19223 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 2255 | 0.000 |
Why?
|
| Vidarabine | 1 | 1987 | 345 | 0.000 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1997 | 3617 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1990 | 700 | 0.000 |
Why?
|
| Granuloma | 1 | 1987 | 315 | 0.000 |
Why?
|
| Kinetics | 1 | 1992 | 6474 | 0.000 |
Why?
|
| Adenoviridae | 1 | 1988 | 1096 | 0.000 |
Why?
|
| Syndrome | 1 | 1990 | 3248 | 0.000 |
Why?
|
| Drug Resistance, Microbial | 1 | 1987 | 860 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1992 | 2186 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 4328 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1987 | 2027 | 0.000 |
Why?
|
| HeLa Cells | 1 | 1988 | 3127 | 0.000 |
Why?
|
| Virus Replication | 1 | 1988 | 2531 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1987 | 2452 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1987 | 4567 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1987 | 3801 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1987 | 4983 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1987 | 6440 | 0.000 |
Why?
|
| Coronary Disease | 1 | 1987 | 6078 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1978 | 6483 | 0.000 |
Why?
|
| Acute Disease | 1 | 1978 | 7141 | 0.000 |
Why?
|
| Epilepsy | 1 | 1978 | 3301 | 0.000 |
Why?
|